Various sensory and motor effects are associated with cancer treatment-induced peripheral neuropathy. The current method for capturing the multifaceted nature of neuropathy includes a combination of objective tests, clinician evaluation, and subjective patient report―an approach that is often not logistically feasible, especially for multisite trials. We report the performance of a brief-yet-comprehensive, easily administered measure, the Treatment-induced Neuropathy Assessment Scale (TNAS), for assessing the severity and course of neuropathy across various cancer treatments.
from The Journal of Pain http://ift.tt/1Mp1eyp
via IFTTT
No comments:
Post a Comment